Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)

NCT06815965 is registered in ClinicalTrials.gov with EIP Pharma Inc as lead sponsor.

NCT NCT06815965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06815965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)
Lead sponsor
EIP Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
October 16, 2024
Completion date
March 25, 2026
Enrollment
26 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

dementia with lewy bodies (dlb)